Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

(Mis)treating the pharmacogenetic incidentalome

Nature Reviews Drug Discovery volume 11, pages 89–90 (2012)Cite this article

Subjects

Abstract

Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to have narrower implications than suggested by initial studies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Committee on a Framework for Development of a New Taxonomy of Disease; National Research Council. Toward precision medicine: building a knowlege network for biomedical research and a new taxonomy of disease. (National Academies Press, Washington DC, 2011).

  2. Kohane, I. S., Masys, D. R. & Altman, R. B. The incidentalome: a threat to genomic medicine. JAMA 296, 212–215 (2006).

    Article  CAS  Google Scholar 

  3. Beutler, E. et al. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359, 211–218 (2002).

    Article  Google Scholar 

  4. Thauvin-Robinet, C. et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J.Med. Genet. 46, 752–758 (2009).

    Article  CAS  Google Scholar 

  5. Murray, M. L. et al. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genetics Med. 13, 998–1005 (2011).

    Article  CAS  Google Scholar 

  6. Kohane, I. S. Using electronic health records to drive discovery in disease genomics. Nature Rev. Genet. 12, 417–428 (2011).

    Article  CAS  Google Scholar 

  7. Johansson, I. & Ingelman-Sundberg, M. CNVs of human genes and their implication in pharmacogenetics. Cytogenetic Genome Res. 123, 195–204 (2008).

    Article  CAS  Google Scholar 

  8. Kohane, I. S. et al. Medicine. Reestablishing the researcher-patient compact. Science 316, 836–837 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isaac S. Kohane, M.D., Ph.D., is at the Harvard Medical School Center for Biomedical Informatics, 10 Shattuck Street, Boston, Massachusetts 02115, USA.,

    Isaac S. Kohane

Authors
  1. Isaac S. Kohane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isaac S. Kohane.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohane, I. (Mis)treating the pharmacogenetic incidentalome. Nat Rev Drug Discov 11, 89–90 (2012). https://doi.org/10.1038/nrd3659

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3659

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research